Biotech Stock news (VRX)(PTLA)(SNY)

Valeant Pharmaceuticals (NYSE:VRX) On Monday March 21, 2016 shares of Valeant were halted pre-market before a major company announcement. The news that eventually came out was that the CEO of the company, Michael J. Pearson, would be resigning from the company. This is definitely bad news as it is never a good thing when a … Read more

Biotech Stock News (MNKD) (SNY) (DVAX) (GSK) (AFFX) (TMO)

Mannkind Corporation (NASDAQ:MNKD) On Tuesday January 5th, 2016 shares of Mannkind fell by more than 48% after it was announced that the collaboration agreement by Sanofi (NYSE:SNY) had been terminated. This agreement was formed way back in 2014 where Sanofi made an upfront payment of $150 million. Sanofi was to take global rights for Afrezza, … Read more

Biotech Stock News (KBIO) (SNY) (CLVS) (AZN) (VRTX)

KaloBios Pharmaceuticals (NASDAQ:KBIO) Last week I wrote how Kalobios was winding down its operations and was looking to put itself up for sale. In an unforeseen event, Martin Shkreli took a big investment in the company sending the share price higher. Before I go any further let me provide a little backstory so that everyone … Read more

MannKind (MNKD) & Sanofi (SNY) Are Likely To Climb More Soon!

MannKind Corporation (NASDAQ: MNKD) | Sanofi SA (ADR) (NYSE: SNY) If you follow my writing here or elsewhere, you know that MannKind stock is one of my favorite topics. The company developed an inhaled insulin called Afrezza that I have high hopes for; and that’s where Sanofi comes in. When it comes to Afrezza, it’s … Read more

Biotech Stock News (RXII)(REGN)(SNY)(ESPR)(ISIS)(BIIB)

Rxi Pharmaceuticals (NASDAQ:RXII) On June 9, 2015 shares of Rxi Pharmaceuticals went up 6% after the company reported that two new key patents were given to the company for use with their self-delivering sd-rxRNA technology platform. The new patents establish a few new details that enhance upon the company’s prospects: First the new patent is … Read more

MannKind (MNKD) Stock | This Will Grow Despite Downgrades

MannKind Corporation (NASDAQ: MNKD) MannKind stock has had a bad run over the last few months. Following a Goldman Sachs downgrade a while back, the stock plummeted; and we’ve seen the same thing this week following a JPMorgan downgrade. However, I’ve got to be honest here…I still see MannKind as a long term gainer despite … Read more

MannKind (MNKD) Runs Into More Afrezza Problems

MannKind Corporation (NASDAQ: MNKD) When you think of MannKind, what’s the first thing that comes to mind? If you’re like most investors, the first thing that comes to mind is Afrezza; the inhaled insulin offered by MannKind. Unfortunately however, Afrezza hasn’t seen the launch that many investors were expecting. As a result, the stock has … Read more

MannKind (MNKD) Stock Falls | Investors Are Concerned Over Afrezza

MannKind Corporation (NASDAQ: MNKD) Last week, as scheduled, MannKind released its earnings report. Although the company did meet estimations with regard to earnings per share, there’s one factor that seems to be upsetting investors. Sales of Afrezza, MannKind’s inhaled insulin, missed the mark with regard to analyst expectations. So below, we’ll talk about Afrezza sales … Read more

MannKind (MNKD) Stock Down On Sanofi (SNY) Earnings

MannKind Corporation (NASDAQ: MNKD) Sanofi SA (ADR) (NYSE: SNY) If you follow my writing here, you know that one of my favorite stocks in biotech is MannKind. Unfortunately however, MNKD is falling in the market today due to the negative report we saw from Sanofi. Nonetheless, I think that the report could turn out to … Read more

MannKind (MNKD) Stock Continues To Get More Attractive

MannKind Corporation (NASDAQ: MNKD) MannKind stock is one of those that investors and traders either love or hate; there just doesn’t seem to be a middle ground. This has led to heavy debate with regard to whether or not the stock is an attractive option. In my personal opinion, not only was it a good … Read more